Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Administration of Inhaled DNase, Baricitinib and Tocilizumab as Rescue Treatment in Severe COVID-19 Patients

NCT05279391 is registered in ClinicalTrials.gov with Democritus University of Thrace as lead sponsor.

NCT NCT05279391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05279391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Administration of Inhaled DNase, Baricitinib and Tocilizumab as Rescue Treatment in Severe COVID-19 Patients
Lead sponsor
Democritus University of Thrace
Phase
Not applicable
Overall status
Unknown status
Start date
October 25, 2020
Completion date
December 31, 2023
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 severe respiratory failure